

Table 15.3.2.1
MAKE60 - logistic regressions
Full analysis set

Imputed values

		Treatment					
		Placebo (N=95)		Ilofotase Alfa (N=109)		Total (N=204)	
MAKE60	n	95		109		204	
No	n (%)	80.34	(84.6)	91.69	(84.1)	172.03	(84.3)
Yes	n (%)	14.66	(15.4)	17.31	(15.9)	31.97	(15.7)
Death or RRT Up To and Including Day 61	n	95		109		204	
No	n (%)	89	(93.7)	104	(95.4)	193	(94.6)
Yes	n (%)	6	(6.3)	5	(4.6)	11	(5.4)
Decrease in eGFR >= 25% on Day 61 Compared to Pre-operative Baseline	n	95		109		204	
No	n (%)	83.96	(88.4)	94.05	(86.3)	178.01	(87.3)
Yes	n (%)	11.04	(11.6)	14.95	(13.7)	25.99	(12.7)

Major adverse kidney events 60 (MAKE60) include: Death up to and including Day 61, any RRT up to and including Day 61, or a decrease in eGFR >= 25% at Day 61 compared to pre-operative Baseline.

For more detail on the used imputation method see SAP. For the imputation, events death and RRT were combined. Averages are based on 100 imputations.

Table 15.3.2.1
MAKE60 - logistic regressions
Full analysis set

Raw values

		Treatment		
		Placebo (N=95)	Ilofotase Alfa (N=109)	Total (N=204)
MAKE60	n	83	95	178
No	n (%)	71 (85.5)	80 (84.2)	151 (84.8)
Yes	n (%)	12 (14.5)	15 (15.8)	27 (15.2)
Death Up To and Including Day 61	n	92	105	197
No	n (%)	90 (97.8)	103 (98.1)	193 (98.0)
Yes	n (%)	2 (2.2)	2 (1.9)	4 (2.0)
RRT Up To and Including Day 61	n	92	104	196
No	n (%)	86 (93.5)	100 (96.2)	186 (94.9)
Yes	n (%)	6 (6.5)	4 (3.8)	10 (5.1)
Decrease in eGFR >= 25% on Day 61 Compared to Pre-operative Baseline	n	81	93	174
No	n (%)	73 (90.1)	81 (87.1)	154 (88.5)
Yes	n (%)	8 (9.9)	12 (12.9)	20 (11.5)

Major adverse kidney events 60 (MAKE60) include: Death up to and including Day 61, any RRT up to and including Day 61, or a decrease in eGFR >= 25% at Day 61 compared to pre-operative Baseline.

Table 15.3.2.1
MAKE60 - logistic regressions
Full analysis set

Adjusted odds ratios for MAKE60

Parameter	Adjusted Odds Ratio	95% Wald Confidence Interval	P-Value (Two-Sided)
Treatment: Ilofotase Alfa vs Placebo	0.936	[0.416; 2.105]	0.8726
Pre-operative baseline sCreat value	0.972	[0.950; 0.995]	0.0172
Baseline eGFR: > 45 mL/min/1.73m2 vs <= 45 mL/min/1.73m2	0.206	[0.053; 0.795]	0.0219
Type of surgery: CABG with 3 or more distal anastomoses vs CABG combined with valve surgery	0.718	[0.318; 1.623]	0.4260

For statistical testing imputed values are used only.

An adjusted odds ratio > 1 indicates a higher risk for a MAKE60 event for 'Ilofotase Alfa' vs 'Placebo' while keeping the other covariates constant, an adjusted odds ratio < 1 indicates a lower risk for a MAKE60 event.

The p-value indicates whether the adjusted odds ratio differs from 1.

Since the result in Table 15.3.1.1 is not statistically significant (p-value = 0.3059), the p-value in this table can only be considered exploratory.

Table 15.3.2.1
MAKE60 - logistic regressions
Full analysis set

Adjusted odds ratios for death and RRT up to and including Day 61

Parameter	Adjusted Odds Ratio	95% Wald Confidence Interval	P-Value (Two-Sided)
Treatment: Ilofotase Alfa vs Placebo	0.656	[0.186; 2.315]	0.5127
Pre-operative baseline sCreat value	1.019	[0.989; 1.051]	0.2094
Baseline eGFR: > 45 mL/min/1.73m ² vs ≤ 45 mL/min/1.73m ²	0.585	[0.087; 3.944]	0.5816
Type of surgery: CABG with 3 or more distal anastomoses vs CABG combined with valve surgery	0.361	[0.100; 1.302]	0.1195

For statistical testing imputed values are used only.

An adjusted odds ratio > 1 indicates a higher risk for a death/RRT event for 'Ilofotase Alfa' vs 'Placebo' while keeping the other covariates constant, an adjusted odds ratio < 1 indicates a lower risk for a death/RRT event.

The p-value indicates whether the adjusted odds ratio differs from 1.

Table 15.3.2.1
MAKE60 - logistic regressions
Full analysis set

Adjusted odds ratios for decrease in eGFR $\geq$ 25% on Day 61 compared to pre-operative Baseline

Parameter	Adjusted Odds Ratio	95% Wald Confidence Interval	P-Value (Two-Sided)
Treatment: Ilofotase Alfa vs Placebo	1.035	[0.405; 2.641]	0.9431
Pre-operative baseline sCreat value	0.950	[0.923; 0.977]	0.0004
Baseline eGFR: > 45 mL/min/1.73m ² vs $\leq$ 45 mL/min/1.73m ²	0.125	[0.025; 0.623]	0.0112
Type of surgery: CABG with 3 or more distal anastomoses vs CABG combined with valve surgery	0.738	[0.291; 1.875]	0.5233

For statistical testing imputed values are used only.

An adjusted odds ratio > 1 indicates a higher risk for an eGFR decrease $\geq$ 25% event for 'Ilofotase Alfa' vs 'Placebo' while keeping the other covariates constant, an adjusted odds ratio < 1 indicates a lower risk for an eGFR decrease $\geq$ 25% event.

The p-value indicates whether the adjusted odds ratio differs from 1.